<DOC>
	<DOCNO>NCT01038505</DOCNO>
	<brief_summary>The investigator center also analyze data last 7 year decease donor ( DD ) live donor ( LD ) kidney transplant recipient randomize 3 immunosuppressive arm 2000 2001 . Thus goal investigator study reduce toxic effect traditional immunosuppressive regimen involve high-dose calcineurin inhibitor agent compare low-dose TAC-MYF low-dose TAC de novo SRL regimen . In order minimize exposure TAC , investigator center previously show favorable outcome use combination Thymoglobulin Zenapax ( Daclizumab ) anti-lymphocyte induction investigator population patient .</brief_summary>
	<brief_title>Comparison Tacrolimus Myfortic Versus Tacrolimus Sirolimus</brief_title>
	<detailed_description>A total 150 randomized patient divide 2 arm : 75 patient randomized receive TAC-SRL , 75 patient receive TAC-MYF .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>NonHLA identical living donor kidney transplant patient Patient previously receive receive organ transplant kidney . Patient receive ABO incompatible donor kidney . Recipient donor know seropositive human immunodeficiency ( HIV ) Hepatitis C virus , Hepatitis B virus antigenemia . Patient current malignancy history malignancy ( within past 5 year ) , except nonmetastatic basal squamous cell carcinoma skin treat successfully , carcinoma insitu cervix treat successfully . Patients significant liver disease , define past 28 day continuously elevate AST ( SGOT ) and/or ALT ( SGPT ) level great 3 time upper value normal range center . Patient uncontrolled concomitant infection and/or severe diarrhea , vomit , active upper gastrointestinal tract malabsorption active peptic ulcer unstable medical condition could interfere study objective . Patient currently participate another clinical trial investigational drug 30 day prior transplant . Patient receive immunosuppressive agent prescribe study . Patient unable take medication orally via nasogastric tube morning second day follow completion transplant procedure ( i.e. , skin closure ) . Patient receiving may require Warfarin , Fluvastatin , herbal supplement study . Concurrent use Astemizole , Pimozide , Cisapride , Terfenadine , Ketoconazole . Patient known hypersensitivity Tacrolimus , Thymoglobulin® , IL2 receptor inhibitor monoclonal antibody , Rapamune , Myfortic® , corticosteroid . Patient pregnant lactating . Patients screening/baseline ( within 96 hour transplant ) total white blood cell count &lt; 4000/mm3 ; platelet count &lt; 100,000/mm3 ; fast triglyceride &gt; 400 mg/dl ( &gt; 4.6 mmol/L ) ; fast total cholesterol &gt; 300 mg/dl ( &gt; 7.8 mmol/L ) ; fast HDLcholesterol &lt; 30 mg/dl ; fast LDLcholesterol &gt; 200 mg/dl . Patient unlikely comply visit schedule protocol . Patient form substance abuse , psychiatric disorder condition , opinion investigator , may invalidate communication investigator . If Tacrolimus institute long 5 day postoperatively .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>